Eukaryotic Initiation Factor (eIF)

CMLD012612 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), designed to disrupt the translation initiation process in eukaryotic cells. This amidino-rocaglate compound features a hydroxamate group, demonstrating significant cytotoxicity in NIH/3T3 cells, with an IC50 value of 2 nM. By modifying the activity of the RNA helicase eIF4A, CMLD012612 exhibits promising anti-neoplastic properties, making it a valuable tool for cancer research and studies focused on translation regulation.

Fosigotifator is an orally active activator of eukaryotic initiation factor 2B (eIF2B), known for its ability to penetrate the blood-brain barrier. By stabilizing the eIF2B complex, Fosigotifator enhances its activity, particularly in the context of pathogenic vanishing white matter (VWM) mutations. As an integrated stress response inhibitor (ISRI), this compound is valuable for research in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS).

CMLD012073 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), functioning through the mechanism of amidino-rocaglates. This compound effectively inhibits cell growth in NIH/3T3 cells with an IC50 value of 10 nM. CMLD012073 disrupts eukaryotic translation initiation by altering the activity of the RNA helicase eIF4A, making it a valuable tool for research applications related to protein synthesis and gene regulation.

CMLD012072 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), specifically targeting eIF4A1 and eIF4A2 through RNA clamping. This amidino-rocaglate compound exhibits significant anti-neoplastic activity, making it a valuable tool for researching the role of eIF4A in cancer biology and therapeutic interventions. Its mechanism of action provides insight into the regulation of protein synthesis in neoplastic cells, facilitating further studies in oncology and molecular biology.

eIF4A3-IN-7 is a potent inhibitor of the eIF4A3 protein, a key regulator of mRNA translation and splicing. This compound demonstrates significant potential for research in cancer and other dysproliferative diseases by modulating gene expression pathways. Its targeted mechanism of action may provide valuable insights into the role of eIF4A3 in tumorigenesis and other pathological conditions.

1,3-Bis[3,5-bis(trifluoromethyl)phenyl]urea is a potent activator of the eIF2α kinase heme-regulated inhibitor. It effectively reduces the levels of the eIF2·GTP·tRNAiMet ternary complex, thereby modulating protein synthesis. This compound also demonstrates significant inhibitory effects on cancer cell proliferation, making it a valuable tool in cancer research and investigations into cellular stress responses.

eIF4E-IN-1 is a potent inhibitor of the eIF4E protein, which plays a critical role in regulating protein synthesis and cell proliferation. This compound effectively targets and inhibits immunosuppressive components, including immune checkpoint proteins such as PD-1, PD-L1, LAG3, TIM3, and IDO. eIF4E-IN-1 demonstrates promising biological activity in the modulation of immune responses, making it a valuable tool for research applications in cancer and infectious disease therapies.

PRXS571 is a potent modulator of the integrated stress response (ISR) in neurons. This compound enhances our understanding of the cellular mechanisms underlying stress adaptation, making it valuable for research into neurodegenerative diseases and other neurological conditions. PRXS571 can be utilized to investigate the role of ISR modulation in various biological processes and therapeutic applications.

RAPT-37-Me is a selective GCN2 inhibitor that demonstrates potent activity with an IC50 of 0.002 μM for GCN2, alongside higher IC50 values of more than 10 μM for PERK, 4.40 μM for HRl, and 1.31 μM for PKR. This compound is valuable for research applications focused on the integrated stress response and its implications in various diseases, offering insights into GCN2-mediated signaling pathways. It is particularly relevant for studies investigating therapeutic interventions that modulate cellular stress responses.

ISR Modulator-1 is a compound that targets the integrated stress response (ISR) pathway. It functions by modulating cellular responses to stressors, enhancing cell survival under adverse conditions. This reagent is valuable for research applications investigating the mechanisms of cellular stress, neurodegenerative diseases, and metabolic disorders.

HD202A is a selective dual inhibitor of MNK1 and MNK2, exhibiting IC50 values of 6.09 nM and 8.06 nM, respectively. This compound effectively inhibits the MNK-eIF4E signaling pathway, leading to downregulation of perilipin 2 and SCD1, while upregulating adipose triglyceride lipase and PPARγ coactivator 1α. HD202A enhances mitochondrial fatty acid oxidation, redox homeostasis, and demonstrates significant effects on metabolic health, including suppression of body weight gain, reduction in hepatic lipid accumulation, and improvement in glucose tolerance and insulin sensitivity. These properties make HD202A a valuable tool for researching metabolic dysfunction-associated steatotic liver disease.

eIF4A-IN-1 is a selective inhibitor of eIF4A, a key protein involved in the regulation of mRNA translation. This compound effectively reduces protein synthesis in cancer cells by disrupting the initiation of translation, thereby providing a valuable tool for investigating tumor biology. eIF4A-IN-1 is applicable in studies focused on cancer therapeutics and understanding the mechanisms of tumorigenesis.

eIF4A3-IN-5 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), specifically targeting eIF4AI and eIF4AII. This compound demonstrates significant potential for investigating eIF4A-dependent diseases, particularly in the context of cancer research. Its ability to modulate eIF4A activity makes it a valuable tool for studying mechanisms of protein synthesis and their implications in tumorigenesis.

ISR Activator 3 (Compound cc81) is a potent activator of the integrated stress response (ISR), targeting RIG-I with a dissociation constant of approximately 0.55 μM. This compound enhances the interferon response in the presence of viral mimicry signals while not inducing lipid droplet clearance. ISR Activator 3 is suitable for research related to neurodegenerative diseases and immune stress mechanisms, providing valuable insights into cellular stress pathways and their implications in various biological contexts.

NVS2.1 is a potent, orally bioavailable readthrough promoter that targets ribosome-associated quality control mechanisms. By promoting the degradation of eRF1, NVS2.1 activates pathways involving GCN1, RNF14, and RNF25, enabling the translation process to bypass premature termination codons. This compound is valuable for research focused on genetic disorders resulting from nonsense mutations.

eIF4E-IN-4 is a selective inhibitor of eukaryotic initiation factor 4E (eIF4E), demonstrating a biochemical activity value of 95 nM. This compound effectively inhibits cap-dependent mRNA translation, exhibiting an IC50 value of 2.5 μM. eIF4E-IN-4 is valuable for research applications related to breast cancer, colon cancer, and head and neck cancer, providing insights into the role of eIF4E in malignancies.

eIF4A3-IN-6 is a selective inhibitor of eukaryotic initiation factor 4A (eIF4A), specifically targeting eIF4AI and eIF4AII. This compound exhibits significant biological activity in disrupting eIF4A-mediated processes, making it a valuable tool for studying eIF4A-dependent diseases, particularly in cancer research. The potential applications of eIF4A3-IN-6 extend to elucidating the role of eIF4A in oncogenic mechanisms and therapeutic interventions.

AMG-34 is a selective GCN2-targeting agent that exhibits an IC50 of 0.395 μM for GCN2, along with IC50 values of 0.010 μM for PERK, 1.07 μM for HR and PKR, and greater than 10 μM for other targets. This compound is instrumental in research focused on the cellular stress response and the role of GCN2 in regulating protein synthesis. Its inhibitory activity makes it a valuable tool for studies exploring the therapeutic potential of modulating the integrated stress response.

MNK1/2-IN-7 is a selective inhibitor of MNK1 and MNK2, primarily targeting the MNK/eIF4E signaling pathway. This compound exhibits potent anticancer activity by effectively inhibiting the phosphorylation of eIF4E, which contributes to reduced cancer cell proliferation. Additionally, MNK1/2-IN-7 demonstrates favorable hERG safety profiles, making it a valuable tool for research applications in oncology, particularly in combination therapies with agents like Ibrutinib.